Subscribe

AACR Annual Meeting

Washington, DC—Lung cancer false- positive rates varied 20-fold across the United States, raising questions about the potential impact on organized screening programs, according to data presented at the 2013 American Association for Cancer Research annual meeting.

Washington, DC—A positive fluorodeoxyglucose-positron emission tomography (FDG-PET) scan distinguished patients with high-risk stage I non–small-cell lung cancer (NSCLC) who may benefit from adjuvant chemotherapy, a retrospective review of a large database showed.

Washington, DC—A positive fluorodeoxyglucose-positron emission tomography (FDG-PET) scan distinguished patients with high-risk stage I non–small-cell lung cancer (NSCLC) who may benefit from adjuvant chemotherapy, a retrospective review of a large database showed.

Washington, DC—Although still in very early-phase testing in humans, the results of 2 small studies in children suggest that reinfusing autologous genetically engineered T cells can reverse acute lymphocytic leukemia (ALL) in children. Both studies were presented at the 2013 American Association for Cancer Research meeting.

All the children had run out of treatment options and were close to death; 2 had a remarkable recovery after T-cell therapy and remain in complete remission.

Chicago, IL—Immunotherapy is nontoxic, tumor-specific, long-term therapy with a long-term memory. The expectation is that once the patient has been treated with immunotherapy, the therapeutic effect will remain and safeguard the patient for life by provoking the immune system to attack any return of the cancer.

There is progress in at least 4 areas: pediatric brain tumors, breast cancer, hepatocellular carcinoma, and generally advanced cancers, according to 4 current studies described at the 2012 American Association for Cancer Research meeting.

Chicago, IL—Several presentations featured at a news conference at the 2012 American Association for Cancer Research meeting highlighted new therapies showing promising results in the early stage of research, potentially charting new options for patients with cancer.

Ibrutinib for B-Cell Lymphoma

Diffuse large B-cell lymphoma (DLBCL) represents 40% of all non- Hodgkin lymphoma. Some 23,000 new cases are diagnosed and 10,000 deaths occur annually in the United States, with a 50% cure rate at best, using chemotherapy and radiation therapy.

Chicago, IL—Targeting prostate cancer with extreme accuracy, using tissue oxygen content to predict its recurrence, and using breast cancer drugs on brain tumors were a few highlights of a news conference on advances in personalized medicine at the 2012 American Association for Cancer Research meeting.

Prostate Cancer

Chicago, IL—Metformin cannot seem to stay out of the news. This antidiabetes drug that is derived from the French lilac is now also thought to possibly protect against liver cancer, lower the risk for oral cancer, improve prognosis of pancreatic cancer in diabetic patients, and increase response to melanoma tumors with BRAF mutations when used in combination with a common cancer drug, according to several studies presented at the 2012 American Association for Cancer Research meeting.

Chicago, IL—For the individual at average risk for disease, whole-genome sequencing (WGS)—mapping the sequence of one’s full set of genetic material—is not a crystal ball to reliably predict future health, according to a study presented at the 2012 American Association for Cancer Research meeting.

Page 2 of 3
Results 11 - 20 of 22
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology